{"nctId":"NCT00449696","briefTitle":"Gel-200 Versus Placebo in Osteoarthritis of the Knee","startDateStruct":{"date":"2006-09"},"conditions":["Osteoarthritis of the Knee"],"count":379,"armGroups":[{"label":"Gel-200","type":"EXPERIMENTAL","interventionNames":["Device: Gel-200"]},{"label":"PBS","type":"PLACEBO_COMPARATOR","interventionNames":["Device: Placebo"]}],"interventions":[{"name":"Gel-200","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with a diagnosis of painful, symptomatic tibio-femoral osteoarthritis of the knee (Grade 1-3 on Kellgren - Lawrence (K-L) score).\n\nExclusion Criteria:\n\n* Subjects with Grade 4 on K-L score\n* Subjects with inflammatory diseases of the knee other than osteoarthritis such as rheumatoid arthritis\n* Serious systemic diseases\n* Female subjects who are pregnant or lactating","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Change From Baseline in WOMAC VAS Stiffness Subscore","description":"Observed WOMAC stiffness subscore on Visual Analog Scale (VAS) of 100 mm; 0 mm meaning no stiffness; 100 mm meaning extreme stiffness. Change in score from baseline to week 13 was calculated as baseline minus week 13. Primary endpoint was the model estimated difference between Gel-200 and PBS placebo.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.9","spread":"30.46"},{"groupId":"OG001","value":"22.5","spread":"28.66"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WOMAC VAS Physical Function Subscore","description":"Observed WOMAC physical function subscore on Visual Analog Scale (VAS) of 100 mm; 0 mm meaning no difficulty; 100 mm meaning extreme difficulty. Change in score from baseline to week 13 was calculated as baseline minus week 13. Primary endpoint was the model estimated difference between Gel-200 and PBS placebo.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":"28.81"},{"groupId":"OG001","value":"21.0","spread":"28.62"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in WOMAC VAS Total Score","description":"Mean of all WOMAC pain, stiffness and physical function subscores on Visual Analog Scale (VAS) of 100 mm; 0 mm meaning no pain, stiffness and difficulty; 100 mm meaning extreme pain, stiffness and difficulty. Change in score from baseline to week 13 was calculated as baseline minus week 13. Primary endpoint was the model estimated difference between Gel-200 and PBS placebo.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","spread":"28.41"},{"groupId":"OG001","value":"21.5","spread":"28.37"}]}]}]},{"type":"SECONDARY","title":"Outcome Measures in Rheumatology Arthritis Clinical Trials (OMERACT)- and the Osteoarthritis Research Society International (OARSI) Response","description":"Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) strict responses defined by changes from baseline in WOMAC pain or physical function subscore ≥50% with absolute changes ≥20 mm (termed strict responders), or ≥20% with absolute changes ≥10mm in 2 of 3 measures of WOMAC pain or physical function subscore or subject global evaluations (termed responders).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.9","spread":null},{"groupId":"OG001","value":"38.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.0","spread":null},{"groupId":"OG001","value":"54.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form - 36 (SF-36)","description":"Scored on physical component scale from 0 (negative health) to 100 (positive health). Calculated norm based with a mean of 50 and a standard deviation of 10.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"9.34"},{"groupId":"OG001","value":"5.3","spread":"9.04"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Visual Analog Scale (VAS) Pain Subscore","description":"Observed WOMAC pain subscore on VAS of 100 mm; 0 mm meaning no pain; 100 mm meaning extreme pain. Change in score from baseline to week 13 was calculated as baseline minus week 13. Primary endpoint was the model estimated difference between Gel-200 and PBS placebo.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":"29.26"},{"groupId":"OG001","value":"22.6","spread":"29.31"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Subject Global Evaluations","description":"Observed subject evaluations on Visual Analog Scale (VAS) of 100 mm; 0 mm meaning excellent feeling in knee joint; 100 mm meaning poor feeling in knee joint. Change in score from baseline to week 13 was calculated as baseline minus week 13. Primary endpoint was the model estimated difference between Gel-200 and PBS placebo.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.8","spread":"33.08"},{"groupId":"OG001","value":"22.0","spread":"30.58"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Physician Global Evaluations","description":"Observed physician global evaluations on Visual Analog Scale (VAS) of 100 mm; 0 mm meaning excellent feeling in knee joint; 100 mm meaning poor feeling in knee joint. Change in score from baseline to week 13 was calculated as baseline minus week 13. Primary endpoint was the model estimated difference between Gel-200 and PBS placebo.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":"28.46"},{"groupId":"OG001","value":"19.0","spread":"26.97"}]}]}]},{"type":"SECONDARY","title":"Acetaminophen Consumption","description":"Weekly mean acetaminophen consumption between weeks 9 and 13.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2007","spread":"3687"},{"groupId":"OG001","value":"2599","spread":"3806"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":249},"commonTop":["Joint swelling","Joint effusion","Arthralgia","Upper respiratory tract infections"]}}}